240
Participants
Start Date
November 1, 2025
Primary Completion Date
October 1, 2026
Study Completion Date
April 1, 2029
Bionic Pancreas
The intervention group will use the iLet Bionic Pancreas (BP) for 13-weeks. They will be trained on the iLet BP system and its components by a Certified iLet Trainer. They will also be trained on how to use the study continuous glucose monitor (CGM) system, blood glucose meter, and ketone meter. Participants will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events and device issues. At the end of 13-weeks, they will complete final visit tasks and will be transitioned back to their pre-study insulin delivery method with guidance provided by a study investigator.
Routine Care
Participants will continue with their current diabetes treatment. Participants will be trained on the use of the study blood glucose meter. They will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events. At the end of 13-weeks, they will complete final visit tasks and will be asked if they would like to participate in the observational extension phase where they will use the iLet Bionic Pancreas for 13 weeks.
University of Colorado Anschutz Medical Campus, Aurora
Massachusetts General Hospital, Boston
Collaborators (1)
Massachusetts General Hospital
OTHER
Beta Bionics, Inc.
INDUSTRY
Ann & Robert H Lurie Children's Hospital of Chicago
OTHER
University of Colorado, Denver
OTHER